InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (1 ops.)
Insider track record
CFODisclosed buys
2
Disclosed sells
1
T+90 hit rate
80%
T+90 mean return
+24.3%
Across 15 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the detailed record of transactions filed by LENZ BRIAN, Chief Financial Officer. Officer active across 1 company, notably Adma Biologics, INC.. Aggregated, 17 disclosures have been recorded. Split: 2 buys · 1 sell. Total volume traded: €937k. History available since 29 September 2021. The latest transaction was filed on 6 March 2024 (Retenue fiscale). Regulator: SEC (Form 4). The full history is openly available.
Declarations17 total
16,677 shares@ US$6.124.5% of flowCommon StockSEC:0001140361-24-012446:0
4,935 shares@ US$5.361.2% of flowCommon StockSEC:0001140361-24-011193:0
8,257 shares@ US$5.261.9% of flowCommon StockSEC:0001140361-24-009843:0
16,908 shares@ US$4.523.3% of flowCommon StockSEC:0001140361-24-001139:0
15,268 shares@ US$3.582.5% of flowCommon StockSEC:0001140361-23-046742:0
211,578 shares@ US$4.597543.2% of flowCommon StockSEC:0001140361-23-040321:0
15,268 shares@ US$3.692.5% of flowCommon StockSEC:0001140361-23-033191:0
15,469 shares@ US$3.312.3% of flowCommon StockSEC:0001140361-23-016460:0
1,559 shares@ US$3.420.2% of flowCommon StockSEC:0001140361-23-010773:0
114,222 shares@ US$3.8720.3% of flowCommon StockSEC:0001140361-23-000872:0
6,993 shares@ US$2.860.9% of flowCommon StockSEC:0001140361-22-045112:0
Ideal exit: 5 Sept 2023 (T+270)
73,678 shares@ US$2.438.8% of flowCommon StockSEC:0001140361-22-036163:0
51,965 shares@ US$1.430.0037% mcap41.2% of flowCommon StockSEC:0001140361-22-019216:0
37,178 shares@ US$1.460.0026% mcap28.7% of flowCommon StockSEC:0001140361-22-011251:0
137,500 shares0Common StockSEC:0001140361-22-008673:0
30,000 shares@ US$1.000.0013% mcap15.1% of flowCommon StockSEC:0001140361-21-035380:0
Ideal exit: 22 Jul 2022 (T+270)
495,000 shares0Common StockSEC:0001140361-21-033355:0
17 of 17 declarations
About LENZ BRIAN
Brian Lenz serves as the Executive Vice President and Chief Financial Officer of ADMA BIOLOGICS, INC. In this role, he is responsible for the financial management of the company, including financial planning and risk management. Brian brings expertise in finance and corporate strategy, contributing to the growth and sustainability of ADMA. His experience enables him to navigate the complex financial landscape and optimize the company's resources.
